Zur Startseite von DrArbeit.de,
der deutschlandweiten Stellenbörse für Diplomarbeiten und Doktorarbeiten


Lupe2

Archiv - Stellenangebot

 

Dies ist ein Angebot aus der Datenbank von DrArbeit.de

Um die Datenbank komfortabel nach weiteren Angeboten durchsuchen zu können, klicken Sie einfach oben oder hier.

 
Archiv-Übersicht     Angebot Nr. 12539

Angebotsdatum: 5. Dezember 2017
Art der Stelle: Doktorarbeit
Fachgebiet: Humanmedizin > Biologie
Titel des Themas: microRNAs in acute myeloid leukemia (aim: PhD, Dr. rer. nat.)

Institut: Division of Hematology and Oncology, Leipzig University Hospital
Adresse:
Prof. Gerhard Behre
Johannisallee 32A, Division of Hematology, Leipzig
04103 Leipzig
Tel.:    Fax.:
Bundesland: Sachsen
Homepage: http://haemonko.uniklinikum-leipzig.de/
E-Mail Kontakt: mail

Beschreibung: The group of Prof. Gerhard Behre from the Division of Hematology and Oncology at Leipzig University is seeking for a highly motivated PhD student (biologischer Doktorand, E13 65%) that wants to join our research group. The focus of our work is on basic molecular and cellular investigations of leukemia biology, especially in the biology of small non-coding RNAs and their role in initiation and maintenance of acute myeloid leukemia (AML). For further information please read our recent publications (e.g. Wurm et al., Nature Comm. 2017) or contact us. In the planned project, we intend to study the suitability of specific microRNAs as therapeutic targets in AML. This includes basic in vitro investigations as well as verification in appropriate mouse models. After a initial period of trainung, the PhD candidate should work independently and self-motivated, should particapte in writing research grants and scientific publications and presenting results at international research meetings.
Methoden: RIP (RNA immune precipitation)-sequencing, microRNA profiling and whole transcriptome profiling with next generation sequencing (NGS) with subsequent bioinformatics using Ingenuity Pathway Analysis (IPA) and functional analysis of microRNAs, e.g. with CRISPR/Cas9 technology and in vivo AML xeno graft mouse models (PDX-AML-cells in NSG mice)
Anfangsdatum: 1. Januar 2018
Geschätzte Dauer: 3 years (aim: PhD, Dr. rer. nat.)
Bezahlung: E13 65%
Papers: 15 most important publications:

1. (IF 12,1) Wurm AA, Zjablovskaja P, Kardosova M, Gerloff D, Bräuer-Hartmann D, Katzerke C, Hartmann JU, Benoukraf T., Fricke S, Hilger N, Müller AM, Bill M, Schwind S, Tenen DG, Niederwieser D, Alberich-Jorda M, Behre G. Disruption of the C/EBPalpha - miR-182 balance impairs granulocytic differentiation, Nat Commun. 2017 Jun 29;8(1):46.

2. (IF 5,6) Namasu CY, Katzerke C, Bräuer-Hartmann D, Wurm AA, Gerloff D, Hartmann J-U, Schwind S, Müller-Tidow C, Hilger N, Fricke S, Christopeit M, Niederwieser D, Behre G. ABR, a novel inducer of transcription factor C/EBPalpha, contributes to myeloid differentiation and is a favorable prognostic factor in acute myeloid leukemia. Oncotarget 2017, in press

3. (IF 12,1) Pulikkan J, Tenen DG, Behre G. C/EBPα deregulation as a paradigm for leukemogenesis. Leukemia, 2017, Jul 19. doi: 10.1038/leu.2017.229. [Epub ahead of print]

4. (IF 7,6) Wurm AA, Tenen DG, Behre G. The Janus-faced nature of miR-22 in hematopoiesis: Is it an oncogenic tumor suppressor or rather a tumor suppressive oncogene? PLoS Genet. 2017 Jan 12;13(1):e1006505

5. (IF 12,1) Gerloff D, Grundler R, Wurm AA, Bräuer-Hartmann D, Katzerke C, Hartmann JU, Madan V, Müller-Tidow C, Duyster J, Tenen DG, Niederwieser D, Behre G. NF-kappa B/STAT5/miR-155 network targets PU.1 in FLT3-ITD-driven acute myeloid leukemia. Leukemia. 2015 Mar;29(3):535-47.

6. (IF 9,4) Braeuer-Hartmann D, Hartmann J-U, Wurm AA, Gerloff D, Katzerke C, Verga Falzacappa M V, Pelicci PG, Mueller-Tidow C, Tenen DG, Niederwieser D and Behre G. PML/RARalpha; -regulated microRNA 181b targets tumor suppressor RASSF1A in acute promyelocytic leukemia. Cancer Research 2015 Aug 15;75(16):3411-24.

7. (IF 11,8) Katzerke C, Madan V, Gerloff D, Bräuer-Hartmann D, Hartmann JU, Wurm AA, Müller-Tidow C, Schnittger S, Tenen DG, Niederwieser D, Behre G. Transcription factor C/EBPα-induced microRNA-30c inactivates Notch1 during granulopoiesis and is downregulated in acute myeloid leukemia. BLOOD. 2013 Oct 3;122(14):2433-42.

8. (IF 11,8) Pulikkan JA, Peramangalam PS , Dengler V, Ho PA, Preudhomme C, Meshinchi S, Christopeit M, Nibourel O, Mueller-Tidow C, Bohlander SK, , Tenen DG, Behre G. C/EBPalpha regulated microRNA-34a targets E2F3 during granulopoiesis and is downregulated in AML with CEBPA mutations BLOOD. 2010 Dec 16;116(25):5638-49.

9. (IF 11,8) Pulikkan JA, Dengler V, Peramangalam PS, Peer Zada AA, Müller-Tidow C, Bohlander SK, Tenen DG, Behre G. Aberrant regulation of a molecular network comprising C/EBPalpha;, microRNA-223 and E2F1 in acute myeloid leukaemia BLOOD, 2010 Mar 4;115(9):1768-78.

10. (IF 12,1) Pulikkan JA, Dengler V, Peer Zada AA, Kawasaki A, Geletu M, Pasalic Z, Bohlander SK, Ryo A, Tenen DG, Behre G. Elevated PIN1 expression by C/EBPalpha-p30 blocks C/EBPalpha induced granulocytic differentiation via c-Jun in AML. Leukemia 2010 May 24 (5):914-23.

11. (IF 11,8) Christopeit M, Schütte V, Theurich S, Weber T, Grothe W, Behre G. Rituximab reduces the incidence of acute graft-versus-host disease. BLOOD 2009 Mar 26;113(13):3130-1

12. (IF 12,1) Christopeit M, Schendel M, Föll J, Müller LP, Keysser G, Behre G: Marked improvement of severe progressive systemic sclerosis after transplantation of mesenchymal stem cells from an allogeneic haploidentical-related donor mediated by ligation of CD137L. Leukemia 2008 May;22(5):1062-4.

13. (IF 11,8) Geletu M, Balkhi MY, Peer Zada AA, Christopeit M, Pulikkan JA, Trivedi AK, Tenen DG, Behre G. Target proteins of C/EBPalpha-p30 in AML: C/EBPalpha-p30 enhances Sumoylation of C/EBPalpha-p42 via up regulation of Ubc9. BLOOD 2007 Nov 1;110(9):3301-9. Epub 2007 Aug 1

14. (IF 31) Pabst T, Mueller BU, Schoch C, Haferlach T, Behre G, Hiddemann W, Zhang DE, Tenen DG: AML1-ETO downregulates the granulocytic differentiation factor C/EBPalpha in t(8;21) myeloid leukemia. Nature Medicine 7: 444, 2001

15. (IF 36) Pabst T, Mueller BU, Zhang P, Radomska HS, Narravula S, Schnittger S, Behre G, Hiddemann W, Tenen DG: Dominant Negative Mutations of CEBPA, encoding CCAAT/enhancer binding protein-alpha (C/EBPalpha), in acute myeloid leukemia. Nature Genetics 27: 263, 2001
Sonstiges: The candidate should preferentially hold a diploma or master in biology, biochemistry or related subjects with a strong background in molecular biology, cell biology, bioinformatics and biochemistry. Experiences in animal handling is very benificial. Good spoken and written english skills are mandatory. The candiate should be able to work independently and to establish experimental strategies to answer biological questions.
For your application, please include:
(a) full curriculum vitae, information on years of experience in research and laboratory work and special skills, list of publications and/or congress participations (if available)
(b) name and contact information (email and telephone numbers) of the diploma/master supervisor as reference
(c) a summary of research interests and long term plans

Archiv-Übersicht